Hi
Stanley,
That all may depend upon the intended audience, and
given the background rationale for this new article, and the attention
of the original ASA publications in 2016 and 2019 by Wasserstein et al, I
am not clear that it is purely for consumption by statisticians. Hence
some of the more technical aspects were not discussed and the scope
limited. Albeit, even within that specific audience there is a wide
spectrum of opinions.
The notion of p values as random variables
is not new. It was covered, to my quick recollection, by Duncan Murdoch
back in 2008 in TAS:
Duncan J Murdoch, Yu-Ling Tsai & James
Adcock
P-Values are Random Variables,
The American
Statistician, 62:3, 242-245
https://www.tandfonline.com/doi/abs/10.1198/000313008X332421I
know Duncan, as he is a former member of the R Core group, and have
interacted with him in that role over the years.
I think that the
rather narrow scope of this new article was to largely refute the
perception that has evolved in some circles, that the ASA's formal
opinion/position, given the prior work, is the need to rapidly move to a
post p value world, and completely reject their use, which is not the
case. So, I do believe that there is important value in this new
article.
A number of the related issues that you raise on effect
sizes and such, as alternatives/supplements to p values, were covered in
the prior work, and I am not sure that they needed to be repeated in
this new article, but opinions can differ.
Regards,
Marc
'Stan
Alekman' via MedStats wrote on 8/11/21 1:11 PM: